Meeting
2015 Gastrointestinal Cancers Symposium
A cost model of capecitabine versus continuous infusional 5-fluorouracil (CI5FU) as chemosensitization during long course radiotherapy in the neoadjuvant treatment of rectal cancer: From the perspective of the Australian health care system.
Authors
Robin John Paterson
Calvary Mater Hospital, Waratah, Australia
Robin John Paterson , Kelly Randall , Fiona Day
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 688)
DOI
10.1200/jco.2015.33.3_suppl.688
Abstract #
688
Poster Bd #
D30
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study final results.
First Author: Stefano Tamberi
Poster
2021 Gastrointestinal Cancers Symposium
A new radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemoradiation in locally advanced or unresectable rectal cancer: The dose-finding part of a phase I/II trial.
First Author: Jaw-Yuan Wang
Poster
2019 Gastrointestinal Cancers Symposium
Integrated profiling the patterns of pathologic response to neoadjuvant chemoradiation and the genomic-based radiation sensitivity in rectal cancer.
First Author: Zhigang Yuan
Poster
2015 ASCO Annual Meeting
A phase II single arm feasibility trial of neoadjuvant chemotherapy (NAC) with oxaliplatin/fluorouracil (OxMdG) then short-course preoperative radiotherapy (SCPRT) then immediate surgery in operable rectal cancer (ORC): COPERNICUS (NCT01263171).
First Author: Simon Gollins